Acetylcysteine Tarbis 600 mg Effervescent Powder

1. What is Acetilcisteína Tarbis and what is it used for.
2. What you need to know before taking Acetilcisteína Tarbis.
3. How to take Acetilcisteína Tarbis.
4. Possible side effects.
5. Storage of Acetilcisteína Tarbis.
6. Contents of the pack and further information.

1. What is Acetilcisteína Tarbis and what is it used for

Acetilcisteína, the active substance of this medicine, belongs to a group of medicines called mucolytics and is used to thin out excessive and/or thick bronchial secretions.

This medicine is indicated to facilitate the elimination of excess mucus and phlegm in respiratory processes that involve excessive or thick mucous secretion, such as: acute and chronic bronchitis, Chronic Obstructive Pulmonary Disease (COPD), emphysema, pulmonary complications of cystic fibrosis, and other related conditions.

2. What you need to know before taking Acetilcisteína Tarbis

Do not take Acetilcisteína Tarbis 600

• If you are allergic to acetilcisteína or any of the other components of this medicine (listed in section 6).
• In children under 2 years of age.

Warnings and precautions

Consult your doctor or pharmacist before starting to take acetilcisteína.

If you are asthmatic or have a severe respiratory disease, you should consult your doctor before taking this medicine.

The possible sulfurous odor (like rotten eggs) of the medicine is characteristic of the active substance, but it does not indicate that the medicine is in poor condition.

If you experience stomach discomfort when taking the medicine, you should stop treatment and consult your doctor or pharmacist. Caution is recommended in patients with peptic ulcer or history of peptic ulcer.

During the first few days of treatment, you may notice an increase in mucus and phlegm that will decrease throughout the treatment.

It should be administered with caution in long-term treatment in patients with histamine intolerance.

Children and adolescents

It is contraindicated in children under 2 years of age.

Other medicines and Acetilcisteína Tarbis

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.

Concomitant therapy with nitroglycerin may cause headache and hypotension should be monitored, which can be severe.

Concomitant administration with the antiepileptic carbamazepine may cause a decrease in the efficacy of carbamazepine.

Do not take it together with antitussive medicines (for cough) or those that reduce bronchial secretions (such as antihistamines and anticholinergics), as it may cause an accumulation of thinned mucus.

When taking any medicine that contains minerals such as iron or calcium, or any medicine with antibiotics (such as amphotericin B, ampicillin sodium, cephalosporins, lactobionate, erythromycin, and some tetracyclines), you should separate its intake from the intake of acetilcisteína by at least 2 hours.

It is not recommended to dissolve acetilcisteína with other medicines.

Taking Acetilcisteína Tarbis with food and drinks

Taking food and drinks does not affect the efficacy of this medicine.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

Its intake should be avoided during breastfeeding.

Driving and using machines

There is no evidence of effects on the ability to drive and use machines.

Warning about excipients

This medicine contains 157.3 mg of sodium per sachet, equivalent to 7.8% of the maximum daily intake of 2 g of sodium recommended by the WHO for an adult.

3. How to take Acetilcisteína Tarbis

Follow exactly the administration instructions of this medicine indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.

The recommended daily dose for adults and children over 7 years is 600 mg of acetilcisteína, 1 sachet of Acetilcisteína Tarbis 600 mg 1 time a day (600 mg of acetilcisteína 1 time a day).

The dose of 600 mg can be administered in three doses of 200 mg each, using acetilcisteína 200 mg.

For its administration, reconstitute the effervescent powder in water until a pleasant-tasting solution is obtained, which is drunk directly from the glass.

Adults, adolescents, and children over 7 years:

200 mg of acetilcisteína (1 sachet of acetilcisteína 200 mg, 3 times a day), every 8 hours. Do not exceed the dose of 3 sachets (600 mg of acetilcisteína) per day.

Use in children and adolescents

Children between 2 and 7 years:

The dose of 600 mg is not recommended.

There are other formulations more suitable for administration to this population.

It is contraindicated in children under 2 years of age.

If you take more Acetilcisteína Tarbis than you should

If you take more acetilcisteína than you should, you may notice: nausea, vomiting, heartburn, and stomach pain, diarrhea, or any other side effect described in section 4. Possible side effects.

In case of overdose or accidental ingestion, consult your doctor or pharmacist or call the Toxicology Information Service, phone 915 620 420, indicating the medicine and the amount taken.

If you have any other questions about the use of this medicine, ask your doctor or pharmacist.

If you forget to take Acetilcisteína Tarbis

Do not take a double dose to make up for the forgotten dose.

If you stop taking Acetilcisteína Tarbis

If you have any other questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The following side effects may occur:

Uncommon (may affect up to 1 in 100 people): hypersensitivity, headache, tinnitus, tachycardia, vomiting, diarrhea, stomatitis, abdominal pain, nausea, urticaria, skin rash, angioedema, pruritus, increased body temperature, hypotension.

Rare (may affect up to 1 in 1,000 people): somnolence, bronchospasm, respiratory distress, gastrointestinal disorders.

Very rare (may affect up to 1 in 10,000 people): allergic reactions, anaphylactic shock, hemorrhage, severe skin reactions such as Stevens-Johnson syndrome and Lyell syndrome, sometimes identified with the concomitant intake of another medicine.

Frequency not known (cannot be estimated from the available data): facial swelling.

If any skin or mucous membrane disorder occurs, the administration of acetilcisteína should be stopped immediately and medical assistance should be sought.

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the Spanish Medicines and Healthcare Products Agency (AEMPS) website: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Acetilcisteína Tarbis

Keep this medicine out of the sight and reach of children.

Do not store above 30°C.

Do not use this medicine after the expiry date stated on the packaging after EXP. The expiry date is the last day of the month indicated.

Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to a pharmacy for disposal. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Contents of the pack and further information

Composition of Acetilcisteína Tarbis

The active substance is acetilcisteína. Each sachet contains 600 mg of acetilcisteína.

The other components (excipients) are: mannitol, colloidal anhydrous silica, sodium saccharin, orange flavor, citric acid, sodium bicarbonate, and maltodextrin.

Appearance of the product and pack contents

Acetilcisteína Tarbis 600 mg is presented in the form of paper and aluminum sachets with an internal polyethylene coating. Each pack contains 20 sachets of white effervescent powder with a slight sulfurous odor.

Marketing authorization holder and manufacturer

Marketing authorization holder

Tarbis Farma, S.L.

Gran Vía Carlos III 94

08028 Barcelona

Spain

Manufacturer

Farmasierra Manufacturing S.L.

Carretera de I

2eyes.

M

E

Date of the last revision of this package leaflet:July 2023

Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) (http://www.aemps.gob.es).